Development & Scientific Writing Week | Navigating FDA requirements: The value of US regulatory expertise in global drug development
At Asphalion, we’re dedicating this week to showcasing the importance of Development, Medical & Scientific Writing. Our team of expert consultants can keep you ahead of market challenges and help you meet all regulatory requirements.
Today, we’re putting the spotlight on the FDA!
Watch the interview in which Bridgette Kunst, Managing Director of Bridge Regulatory Affairs and ASPHALION’s US Agent, joins Montse de Castellarnau from ASPHALION to discuss when companies should start considering FDA requirements as part of their global development programmes, how a US Agent can add value throughout the development process, and some of the most common challenges encountered during IND preparation.
ASPHALION’s US regulatory Development & Scientific Writing expertise covers:
- Regulatory strategy: FDA regulatory roadmaps to define the best US regulatory pathway, feasibility reports, due diligence and gap analyses of existing US dossiers.
- Regulatory submissions: Preparation, submission and maintenance of Pre-IND meeting packages, INDs, NDAs, BLAs, ANDAs, DMFs, Orphan Drug Designations (ODDs), Paediatric Study Plans (PSPs), Paediatric Investigation Plans (PIPs) and other regulatory applications.
- Scientific and medical writing: CMC, clinical and non-clinical documentation, including Integrated Summary of Safety (ISS) and Integrated Summary of Effectiveness (ISE).
- FDA meeting support: Meeting arrangements and preparation of meeting packages.
Through our collaboration with experienced US regulatory professionals, we help pharmaceutical and biotechnology companies navigate FDA requirements and define the right regulatory strategy for their products.
Watch the full interview to gain insights into US regulatory considerations and how to navigate the FDA landscape: https://youtu.be/gOkEiBFRs3E
Need support with your FDA regulatory strategy? Let’s talk! [email protected]






